Stimulation with peroxisome proliferator–activated receptor gamma (PPARγ) was able to reduce this ET-1 overexpression, demonstrating the potential for PPARγ agonists as therapeutics for PAH. The gene discussed is EDN1; the disease is pulmonary arterial hypertension.